Get the Stockscreener App
3.74
0.00%
0.00
After Hours:
3.71
-0.03
-0.80%
Compass Therapeutics Inc stock is traded at $3.74, with a volume of 1.08M.
It is up +0.00% in the last 24 hours and up +1.08% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
See More
Previous Close:
$3.74
Open:
$3.77
24h Volume:
1.08M
Relative Volume:
0.67
Market Cap:
$517.18M
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-10.69
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
-9.00%
1M Performance:
+1.08%
6M Performance:
+97.88%
1Y Performance:
+120.00%
1-Day Range:
$3.65
$3.95
1-Week Range:
$3.63
$4.265
52-Week Range:
$1.27
$4.86
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
3.74 | 641.68M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Can Compass Therapeutics Inc. recover in the next quarter2025 Investor Takeaways & AI Driven Price Forecasts - newser.com
How to interpret RSI for Compass Therapeutics Inc. stockMarket Performance Summary & Fast Entry Momentum Alerts - newser.com
Compass Therapeutics to Participate in Upcoming November Investor Events - Yahoo Finance
How Compass Therapeutics Inc. stock performs in weak economyJuly 2025 Fed Impact & Community Shared Stock Ideas - newser.com
Institutional investors in Compass Therapeutics, Inc. (NASDAQ:CMPX) lost 9.0% last week but have reaped the benefits of longer-term growth - Yahoo Finance
Will Compass Therapeutics Inc. stock outperform growth indexesTrade Volume Report & Real-Time Sentiment Analysis - newser.com
How Compass Therapeutics Inc. stock performs in stagflationTrade Risk Assessment & Long Hold Capital Preservation Plans - newser.com
Is Compass Therapeutics Inc. stock recession proof2025 Growth vs Value & Consistent Income Trade Recommendations - newser.com
Why Compass Therapeutics Inc. stock is seen as undervaluedJuly 2025 Catalysts & Weekly Setup with ROI Potential - newser.com
Will Compass Therapeutics Inc. stock split attract more investorsMarket Risk Summary & Safe Swing Trade Setup Alerts - newser.com
How Compass Therapeutics Inc. stock trades before earningsJuly 2025 Breakouts & Reliable Trade Execution Plans - newser.com
Piper Sandler Remains Bullish on Compass Therapeutics (CMPX) - Insider Monkey
14 Stocks Under $5 with Highest Upside Potential - Insider Monkey
How to track smart money flows in Compass Therapeutics Inc.Quarterly Investment Review & Weekly High Potential Alerts - newser.com
Compass Therapeutics’ Phase 1 Study of CTX-8371: A Potential Game-Changer in Cancer Treatment - TipRanks
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):